This trial is active, not recruiting.

Condition multiple myeloma
Treatments thalidomide, cyclophosphamide, dexamethasone, thalidomide, dexamethasone, thalidomide, melphalan, prednisone
Phase phase 3
Sponsor Grupo de Estudos Multicentricos em Onco-Hematologia
Start date January 2007
End date December 2011
Trial size 64 participants
Trial identifier NCT01532856, GBRAM0002


This protocol is an international, multicenter, comparative, open and randomized study designed to compare the safety and efficacy (in terms of response rate) from three induction chemotherapy schemes -Thalidomide/Cyclophosphamide/Dexamethasone versus Thalidomide/Dexamethasone versus Thalidomide/Melphalan/Prednisone. Finally, this study is also designed to compare the safety and efficacy (in terms of duration of response) of two maintenance chemotherapy regimens - Thalidomide/Prednisone versus Thalidomide. Each treatment arm will include 100 patients and assessments and scheduled visits will be conducted in three periods: Pre-treatment, treatment and monitoring. Security will be evaluated by monitoring all adverse events, physical examination, vital signs and biochemical studies. Response to treatment will be evaluated according to the EBMT21 criteria and will be assessed on day 1 of each cycle of induction, at the end of nine cycles of induction therapy and monthly during the first year of maintenance therapy and every 3 months thereafter.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(Active Comparator)
Thalidomide + Cyclophosphamide + Dexamethasone
thalidomide, cyclophosphamide, dexamethasone
Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
(Active Comparator)
thalidomide + dexamethasone
thalidomide, dexamethasone
Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally, in three pulses (days 1 to 4, 9 to 12 and 17 20) odd cycles and a single pulse treatment in pairs cycles, during 9 cycles of 28 days each cycle
(Active Comparator)
thalidomide + melphalan + prednisone
thalidomide, melphalan, prednisone
thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle; melphalan - 4 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle; prednisone - 40 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle

Primary Outcomes

Response rate
time frame: 36 months
Duration of response
time frame: 36 months

Secondary Outcomes

overall survival
time frame: 36 months
event-free survival
time frame: 36 months
progression free-survival
time frame: 36 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - > 65 years old and non candidate for autologous stem cell transplant - Patient must be newly diagnosed with Multiple Myeloma according to establish criteria symptoms. Steroid pulses administration are allowed for any required emergency prior to starting induction therapy or bisphosphonates administration - Patient must have measurable disease, defined as follows: for secretory multiple myeloma, measurable disease is defined by the presence of measurable monoclonal component in serum or in urine excretion if light chain is greater than or equal to 200 mg/24 hours(Annex 5) - Measured ECOG < 2 state level. - The patient must have a life expectancy greater than 3 months. - Adequate laboratory values prior to induction treatment initiation, defined as follow: 1. Platelet count ≥ 50000/mm3, hemoglobin ≥ 8 g / dl and absolute neutrophil count ≥ 1000/mm3. Lower values are permitted if they are due to BM infiltration. 2. Corrected serum calcium ≤ 14mg/dl. 3. Aspartate transaminase (AST): ≤ 2.5 x normal upper limit. 4. Alanine transaminase (ALT):): ≤ 2.5 x normal upper limit. 5. Total bilirubin: ≤ 1.5 x normal upper limit. 6. Serum creatinine ≤ 2 mg / dl. - Men (including vasectomy done) must use barrier contraception (latex condoms) when having sex with women of potential childbearing, and for at least four weeks after thalidomide last dose. Exclusion Criteria: - Non-secretory MM. - Previous treatment for multiple myeloma with the exception of steroid pulses for any emergency that requires treatment before beginning the induction, administration of bisphosphonates or radiation therapy. - Basal peripheral neuropathy higher than grade 2 within 14 days of inclusion. - Known thalidomide hypersensitivity. - Use of any investigational agent within 30 days prior to their inclusion. - Known human immunodeficiency virus(HIV) infection, detectable surface antigen of hepatitis B or active infection by the hepatitis C viruses - Myocardial infarction within 6 months prior to inclusion or heart functional class III or IV according to New York Heart Association (NYHA) heart failure, angina, uncontrolled ventricular arrhythmias or acute ischemia detected by electrocardiogram or conduction system abnormalities. - Participation in another clinical trial or receiving any investigational agent.

Additional Information

Official title Iberoamerican Phase III International Study, Open, Multicenter, Randomized, Comparative of Thalidomide / Cyclophosphamide / Dexamethasone Versus Thalidomide / Dexamethasone Versus Thalidomide / Melphalan / Prednisone as Induction Therapy Followed by Maintenance Therapy With Thalidomide + Prednisone Versus Thalidomide Alone in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65years.
Principal investigator Vania Hungria, PhD MD
Trial information was received from ClinicalTrials.gov and was last updated in February 2012.
Information provided to ClinicalTrials.gov by Grupo de Estudos Multicentricos em Onco-Hematologia.